Neuropace Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuropace, Inc. on June 24, 2025, reporting events occurring on June 20, 2025. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer (CFO) and the appointment of a successor.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company. The document focuses exclusively on executive compensation and transition arrangements.
Material Changes
- Departure of CFO: Rebecca Kuhn resigned as Chief Financial Officer and Vice President, Finance and Administration effective June 20, 2025. She will transition to the role of Senior Strategic Advisor—Finance.
- Appointment of New CFO: Patrick F. Williams was appointed as Chief Financial Officer, effective June 20, 2025. He will also serve as the principal financial officer and principal accounting officer.
- Compensation Arrangements:
- Ms. Kuhn (Outgoing): Entitled to 12 months of base salary as severance, reimbursement of up to 18 months of COBRA premiums, and a pro-rated 2025 bonus of $88,885. Outstanding equity awards will continue to vest during the consulting period through June 19, 2026.
- Mr. Williams (Incoming): Base salary of $500,000 per year with a target annual bonus of 60%. He received sign-on equity awards (10,370 RSUs and options for 17,600 shares) and new hire equity awards (41,480 RSUs and options for 70,350 shares), vesting over four years.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed relates to the transition of financial leadership and the associated severance and compensation costs. The separation agreement and employment offer letter are subject to the execution of a general release of claims by Ms. Kuhn.
Investor Verification Checklist
- Verify the terms of the Separation Agreement and Offer Letter when filed as exhibits to the Form 10-Q for the quarter ended June 30, 2025.
- Monitor the Company's subsequent filings for any impact of the leadership transition on financial reporting or operational strategy.
- Review the vesting schedules and exercise prices for the new equity awards granted to Mr. Williams to assess potential dilution.
- Confirm the duration and scope of Ms. Kuhn's consulting role to understand the timeline for the full transition of duties.